Capricor Investors File Securities Class Action Over Deramiocel Misrepresentation

Multiple law firms have filed class action lawsuits against Capricor Therapeutics, Inc., alleging the company misled investors about the prospects and data of its cell therapy candidate, deramiocel, particularly regarding its approval pathway with the FDA. Capricor had initially announced positive progress and an expected FDA Prescription Drug User Fee Act action date, but the FDA later issued a Complete Response Letter denying the Biologics License Application due to insufficient evidence of effectiveness and manufacturing concerns. The lawsuits claim Capricor made false and misleading statements by overstating the drug’s efficacy and concealing regulatory setbacks, which caused significant declines in the company’s stock price. Investors who purchased shares between October 9, 2024, and July 10, 2025, are encouraged to consider their legal rights and may apply to be lead plaintiffs by September 15, 2025. Several prominent law firms, including Kirby McInerney LLP, Bernstein Liebhard LLP, Levi & Korsinsky LLP, and Holzer & Holzer, LLC, are representing shareholders in these actions. The litigation seeks to recover losses stemming from Capricor’s alleged securities fraud related to the Phase 2 HOPE-2 trial data and FDA communications.